Vol. 6 No. 11 (2026): November
Reimbursement Reviews

Inebilizumab (Uplizna)

decorative image of the issue cover

Published November 3, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses inebilizumab (Uplizna), 10 mg/mL, single-dose vials containing 100 mg inebilizumab in 10 mL solution, IV infusion.
  • Indication: Inebilizumab for injection is indicated for the treatment of IgG4-RD in adult patients to reduce the frequency of flares.